JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

Search

Arbutus Biopharma Corp

Открыт

4.74 4.64

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

4.47

Макс.

4.74

Ключевые показатели

By Trading Economics

Доход

27M

2.5M

Продажи

9M

11M

Рентабельность продаж

23.494

Сотрудники

44

EBITDA

27M

2.6M

Рыночная статистика

By TradingEconomics

Рыночная капитализация

217M

857M

Предыдущая цена открытия

0.1

Предыдущая цена закрытия

4.74

Техническая оценка

By Trading Central

Уверенность

Weak Bearish Evidence

Arbutus Biopharma Corp График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

28 окт. 2025 г., 23:50 UTC

Популярные акции

Stocks to Watch: Caesars, Enphase, Mondelez, Teradyne

28 окт. 2025 г., 23:25 UTC

Отчет

SK Hynix Posts Record Earnings on Continued AI-Chip Demand

28 окт. 2025 г., 23:18 UTC

Отчет

Booking 3Q Sales Rise as U.S. Travel Demand Stabilizes -- Update

28 окт. 2025 г., 22:20 UTC

Отчет

Visa Sales Jump as Consumers Keep Spending -- 2nd Update

28 окт. 2025 г., 22:13 UTC

Отчет

Wal-Mart de Mexico Net Profit Falls in 3Q

28 окт. 2025 г., 21:38 UTC

Отчет

Correction to Visa Sales Jump Article

28 окт. 2025 г., 21:17 UTC

Отчет

OrthoPediatrics Wins FDA Approval for Surgery Plating System; 3Q Revenue Rises

28 окт. 2025 г., 21:07 UTC

Отчет

Visa Sales Jump as Consumers Keep Spending -- Update

28 окт. 2025 г., 21:02 UTC

Отчет

Mondelez Tempers Outlook as Costs Rise

28 окт. 2025 г., 23:51 UTC

Обсуждения рынка

Nikkei May Rise on Easing U.S.-China Tensions -- Market Talk

28 окт. 2025 г., 23:42 UTC

Обсуждения рынка

Gold Edges Lower on Possible Position Adjustments Ahead of FOMC Decision -- Market Talk

28 окт. 2025 г., 23:02 UTC

Отчет

SK Hynix: HBM4 Shipments to Start in 4Q, Ahead of Full-Scale Sales Expansion in 2026

28 окт. 2025 г., 23:01 UTC

Отчет

SK Hynix: Completed Discussions With Key Customers About 2026 HMB Supply

28 окт. 2025 г., 22:46 UTC

Отчет

SK Hynix: Co. Secured Full Customer Demand for Its Entire DRAM and NAND Production for Next Yr >000660.SE

28 окт. 2025 г., 22:45 UTC

Отчет

SK Hynix 3Q Net KRW12.6T >000660.SE

28 окт. 2025 г., 22:44 UTC

Отчет

SK Hynix 3Q Rev KRW24.44T >000660.SE

28 окт. 2025 г., 22:43 UTC

Отчет

SK Hynix 3Q Net Profit Beat FactSet-Compiled Consensus

28 окт. 2025 г., 22:42 UTC

Отчет

SK Hynix 3Q Net KRW12.598T Vs. Net KRW5.753T >000660.SE

28 окт. 2025 г., 22:40 UTC

Отчет

SK Hynix 3Q Rev KRW24.449T Vs. KRW17.573T >000660.SE

28 окт. 2025 г., 22:40 UTC

Отчет

SK Hynix 3Q Oper Pft KRW11.383T Vs. Pft KRW7.030T >000660.SE

28 окт. 2025 г., 22:22 UTC

Отчет

Pharmaron Beijing: Higher Contributions From Clinical-Development Services Supported Results >300759.SZ

28 окт. 2025 г., 22:22 UTC

Отчет

Pharmaron Beijing: Higher Contributions From Laboratory Services Supported Results >300759.SZ

28 окт. 2025 г., 22:22 UTC

Отчет

Pharmaron Beijing 3Q Net CNY439.52M, Up 42.5% on Year >300759.SZ

28 окт. 2025 г., 22:20 UTC

Отчет

Pharmaron Beijing 3Q Rev CNY3.64B, Up 13.4% on Year >300759.SZ

28 окт. 2025 г., 22:02 UTC

Отчет

Review & Preview: Earnings Extravaganza -- Barrons.com

28 окт. 2025 г., 21:42 UTC

Обсуждения рынка
Отчет

Global Equities Roundup: Market Talk

28 окт. 2025 г., 21:42 UTC

Обсуждения рынка
Отчет

Mondelez Says Cocoa Costs Peaked Heading Into Spooky Season -- Market Talk

28 окт. 2025 г., 21:20 UTC

Отчет

Wal-Mart de Mexico 3Q EBITDA MXN25.27B, Up 3.3% on Year

28 окт. 2025 г., 21:19 UTC

Отчет

Wal-Mart de Mexico 3Q Rev MXN241.52B, Up 4.9% on Year

28 окт. 2025 г., 21:18 UTC

Отчет

Wal-Mart de Mexico 3Q Net MXN11.75B, Down 9.2% on Year

Сравнение c конкурентами

Изменение цены

Arbutus Biopharma Corp Прогноз

Консенсус по рейтингу

By TipRanks

0 ratings

0

Покупка

0

Удержание

0

Продажа

Техническая оценка

By Trading Central

3.255 / 3.365Поддержка и Сопротивление

Краткосрочная

Weak Bearish Evidence

Среднесрочная

Bullish Evidence

Долгосрочная

Weak Bullish Evidence

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
help-icon Live chat